Chemotactic responses of eosinophils from patients with allergic rhinitis to 5 STO-2-derived eosinophil chemotactic factors (ECF), IL-3, IL-5 and GM-CSF were examined. The patients were divided into two groups: patients with perennial allergic rhinitis sensitive to Dermatophagoides farinae and those with seasonal allergic rhinitis sensitive to Japanese cedar pollen. There was no essential difference between chemotactic response of eosinophils from the former to STO-2-derived ECF and that from healthy individuals. However, eosinophils from patients with seasonal allergic rhinitis failed to respond to one of the STO-2-derived ECFs, ECF-P19. Before and after nasal antigen provocation, no change occurred in the chemotactic profiles. Furthermore, we found that eosinophils from both types of patients with allergic rhinitis responded not only to IL-3 and GM-CSF but also to IL-5 unlike those of healthy individuals.

Keywords:
Eosinophil heterogeneity, Eosinophil chemotactic factor, Allergic rhinitis
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.